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the reliability of the anchor and the estimated MID. METHODS: We performed a 
simulation study in which the reliability of the anchor used for MID estimation was 
varied systematically. Features of real-life data (e.g., skewed distribution, discreteness 
of PRO scale) and anchors were used to generate simulated PRO scales and anchors. 
MIDs were then estimated on the basis of the simulated data. RESULTS: Compared 
to the MID value obtained with an anchor with perfect reliability (r = 1), a marked 
attenuation of the MID was observed when reducing the reliability of the anchor. 
Thus, an anchor with reliability 0.7 gave rise to a 24% to 35% decrease of the MID 
estimate and an anchor with reliability 0.5 led to a 45% to 55% reduction. Based on 
the ﬁ ndings and on theoretical considerations, we suggest a method for bias correction. 
CONCLUSIONS: When determining the MID of a PRO scale by an anchor-based 
method, the reliability of the anchor plays a crucial role. Anchors with poor to moder-
ate reliability may lead to considerable underestimation of the MID. Bias correction 
is possible provided the reliability of the anchor is known. 
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OBJECTIVES: Value-based pricing has recently been discussed by international orga-
nizations as a means to estimate a drug price that is linked to the beneﬁ ts it offers 
patients and society. However, one of the challenges with value-based pricing is 
determining the optimal threshold for health policy decision-making. The World 
Health Organization (WHO) has recommended using multiples of a country’s per 
capita GDP as the value threshold. In this study, pharmacoeconomic modeling was 
used to estimate a value-based monthly price for a hypothetical new cancer drug that 
provides a 3-month survival to patients with metastatic colorectal cancer (mCRC). 
METHODS: A decision model was developed to simulate progression free and overall 
survival in mCRC patients receiving standard chemotherapy ± the new drug. Out-
comes for cancer control and side effects were abstracted from randomized trials in 
mCRC. Costs for chemotherapy were obtained from Canadian cancer centers. Utility 
estimates measured as quality-adjusted life-years (QALYs) were determined by inter-
viewing 24 oncology nurses and pharmacists using the Time Trade-Off technique. The 
monthly price of the new drug was then modeled using a threshold of $117,000 per 
QALY gained, which is three times the Canadian per capita GDP, as recommended 
by the WHO. RESULTS: The analysis suggested that a monthly price of $2180 would 
be considered cost-effective from the Canadian public health perspective. If the drug 
were able to improve patient quality of life or survival from 3 to 6 months, the monthly 
price could increase to $4100 and $3430 and offer the same value. CONCLUSIONS: 
The use of the WHO criteria for estimating a value-based price is feasible. However, 
one of the challenges would be to identify an appropriate threshold that would provide 
a balance between what governments can afford to pay and the commercial viability 
of the product in the reference country.
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OBJECTIVES: Many countries are adapting their pharmaceutical reimbursement 
system, increasingly emphasizing the role of pharmacoeconomics in decision-making. 
The aim of our study is to analyze European regulatory systems to obtain insight into 
best practice systems that deliver value for money. METHODS: The analytical Hutton 
Framework was used for comparing and assessing “fourth hurdle” drug reimburse-
ment systems in the The Netherlands, Belgium, Sweden, and France. We investigated 
policy documents, explored literature, and conducted interviews with policymakers 
and representatives of the pharmaceutical industry. RESULTS: All systems have a 
centralized decision body, even though the ﬁ nancial responsibility may be regional 
(Sweden). Only in Sweden, the minister has no role at the individual reimbursement 
decision level. None of the systems has a fully independent evaluation process and the 
impact of the systems is mainly assessed on drug expenditure. All countries make 
efforts to increase transparency. However, in Sweden manufacturers may withdraw 
their application before the ﬁ nal reimbursement decision, guaranteeing conﬁ dentiality 
at the cost of less transparency. Policies to deal with uncertainty vary per country: 
ﬁ nancial risk-sharing agreements by price/volume contracts—France—versus out-
comes-based agreements for expensive inpatient drugs—the The Netherlands. The 
actual value of a drug and disease severity is reﬂ ected in the level of reimbursement 
in France and Belgium, whereas in the The Netherlands and Sweden, enlisted drugs 
are fully reimbursed. All countries attempt to increase the importance of pharmaco-
economics in decision-making. However, no country expresses the relative importance 
of cost-effectiveness compared to other criteria nor applies a strictly deﬁ ned threshold. 
CONCLUSIONS: This study reveals that while there is a convergence in scientiﬁ c 
evaluation processes, important differences remain between the Dutch, Belgian, 
Swedish, and French regulatory frameworks. All countries recognize that pharmaco-
economics has a place in decision-making on value for money, but for the time being, 
pharmacoeconomics seems to play a rather undeﬁ ned role.
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OBJECTIVES: Finnish retail prices for drugs are determined with a pricing scheme 
(PS). The PS is of the form “multiplier × wholesale price + ﬁ xed sum.” The multiplier 
ranges from 1.125 to 1.5 (being smaller for higher wholesale prices), whereas the ﬁ xed 
sum ranges from 0.5 to 47.68 euros (being larger for higher wholesale prices). 
Although PS is regressive, it nevertheless provides higher absolute pharmacy margins 
for drugs with higher wholesale prices. At the lower end of wholesale prices, PS results 
in retail prices that do not cover dispensing costs. Despite this, the retail prices (exclud-
ing VAT 8%) are used to represent all drug and drug delivery costs in economic evalu-
ations. This study assesses the impact of this Finnish system-derived “distortion” in 
cost-effectiveness analyses. METHODS: The cost utilities of new hypothetical treat-
ments were assessed in a setting where the new and old treatments produce different 
amounts of quality-adjusted life-years (QALYs) and the only cost difference comes 
from the pharmaceutical prices. The treatments are assumed not to differ regarding 
the real costs of drug delivery and patient survival. The PS-induced computational 
cost difference was deducted from the retail price differences of new and old treatments 
to estimate the impact of PS on the incremental cost-effectiveness ratios (ICER). 
RESULTS: The computational cost differences due to PS ranged from 7.3 to 1 951 
euros and the QALYs gained ranged from 0.004 to 0.070 in estimated scenarios. The 
respective ICERs increased by 104 to 487 840 euros/QALY due to the PS. CONCLU-
SIONS: The PS signiﬁ cantly worsens the ICERs obtained for more expensive and often 
innovative pharmaceuticals. The Finnish PS is problematic when the aim is to provide 
optimal, cost-effective treatments to Finnish patients. In the current form, the PS 
discourages innovation and may prevent reimbursement of otherwise cost-effective 
treatments.
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OBJECTIVES: To develop a framework for integrating pricing and reimbursement 
with health economics and outcomes research and health policy to achieve commer-
cially desirable prices and levels of access in 2010 and beyond. METHODS: A review 
of recent pricing policy and regulatory changes of countries, especially those in the 
ﬁ nancially troubled Eurozone, was conducted. This was supplemented by a review of 
P&R decisions for a selection of drug launches between 2005 and 2009 and catego-
rized according to the level of therapeutic innovation and disease type (conventional, 
rare diseases, oncology). a search was performed on the OHE and NHS EED databases 
and HTA reports to establish the level of published value evidence in support of these 
launches, and ﬁ nally, the components of most importance to a market access strategy 
were identiﬁ ed and validated through interviews across different stakeholder types. 
RESULTS: The review identiﬁ ed since January 2010, there have been 11 pricing policy 
and regulatory changes. From the review of recent P&R decisions and stakeholder 
interviews, the main components identiﬁ ed were: competitive and environmental 
analysis (market assessment, reimbursement, revenue forecasts, policy trends); analysis 
of payer’s decision drivers (payer, physician, and other stakeholder qualitative 
research); value demonstration (value hypotheses, economic modeling, patient-
reported outcomes, scientiﬁ c advice); pricing strategy (price targets, cross-market 
revenue optimization modeling, country launch sequencing, scenario planning); and 
local market access tactics (HTA, risk sharing, contracting negotiations with payers). 
The review of the P&R decisions also demonstrated an increasing trend toward 
deployment of risk-sharing schemes since 2008. CONCLUSIONS: Development of a 
successful market access strategy requires an understanding of pricing, health econom-
ics and outcomes research, health technology assessment (HTA), and health policy, 
and continually keeping vigilant and adapting to rapid changes in the policy environ-
ment. This research gives direction to health economics, P&R, and government affairs 
professionals for the development of an integrated framework for the design and 
implementation of a global market access strategy. 
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BACKGROUND: In literature, economic models of ﬂ u vaccination in elderly (65+) 
most often consider the target population as one homogeneous age group evaluated 
during a 1-year time period (= 1-year 65+ group cohort model). Because the mortality 
